相似文献
1
Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Indian J Pharmacol. 2016 Jul-Aug;48(4):458-459. doi: 10.4103/0253-7613.186214.
2
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.
3
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.
4
Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
J Clin Oncol. 2016 Apr 10;34(11):e97-8. doi: 10.1200/JCO.2013.50.1320. Epub 2014 Sep 29.
5
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
6
miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Leuk Lymphoma. 2017 Aug;58(8):1981-1984. doi: 10.1080/10428194.2016.1272681. Epub 2017 Jan 16.
7
Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
J Cancer Res Ther. 2014 Oct-Dec;10(4):1107-8. doi: 10.4103/0973-1482.146095.
8
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.
9
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
10
Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.
Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):727-729. doi: 10.4103/0378-6323.186477.
引用本文的文献
1
Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review.
Cureus. 2025 Jun 1;17(6):e85196. doi: 10.7759/cureus.85196. eCollection 2025 Jun.
2
The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review.
Int J Clin Pharm. 2024 Apr;46(2):368-381. doi: 10.1007/s11096-023-01671-0. Epub 2023 Dec 26.
本文引用的文献
1
Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.
Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.
2
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
3
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x. Epub 2008 Apr 3.
4
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
5
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.
Nature. 1983;306(5940):239-42. doi: 10.1038/306239a0.
Zotero 插件